<DOC>
	<DOCNO>NCT01803035</DOCNO>
	<brief_summary>The purpose study determine efficacy topical antibiotic LTX-109 term clinical microbiological response treatment impetigo .</brief_summary>
	<brief_title>A Phase II Study Evaluate Efficacy Safety Two Doses LTX-109 Impetigo</brief_title>
	<detailed_description>The study randomize , double-blind , placebo control study . Up 210 patient enrol three treatment group receive 1 % LTX-109 , 2 % LTX-109 placebo three time daily ( TID ) 5 day . Patients randomized receive LTX-109 placebo ratio 1:1 dos . Patients ≥2 year non-bullous impetigo enrol study . Study candidacy determine dermatological examination , medical history , clinical diagnosis non-bullous impetigo positive Gram-stain . Patients meet eligibility randomize one treatment group . A safety visit perform Day 4 . Clinical response evaluate clinical success , clinical improvement clinical failure accord definition protocol one visit - Day 4 ( -1 ) , Day 6 ( +2 ) Day 12 ( +2 ) , derive Skin Infection Rating Scale ( SIRS ) score target lesion . Bacteriological response evaluate culture swab collect target lesion . Success failure define presence non-presence causative pathogen ( bacteria isolate baseline consider causative pathogen : S. aureus S. pyogenes ) . Bacteriological swab collect pus/exudate available Day 4 ( -1 ) , Day 6 ( +2 ) Day 12 ( +2 ) , exudate/pus available target lesion . No pus/exudate consider elimination causative pathogen , consider bacteriological success .</detailed_description>
	<mesh_term>Impetigo</mesh_term>
	<criteria>Patients ≥ 2 year age . Signed write informed consent document patient , parent , legal guardian caretaker . Positive Gramstain target lesion show Grampositive cocci . Clinical diagnosis primary nonbullous impetigo per protocol . Candidate treatment topical antibacterial Skin Infection Rating Scale ( SIRS ) ≥ 4 least three five primary sign symptom present baseline include score 1 great exudate/pus . Total lesion area ≤ 20 cm2 . Single lesion exceed 2 cm2 . No known medical condition investigator opinion may interfere study participation put patient additional risk . Unwillingness inability patient , parent , legal guardian caretaker comply requirement protocol . Presence skin disease near investigational target area treat . The disease widespread severe , opinion investigator , patient need oral antibiotic treatment . History hepatitis B C , HIV , AIDS , immunodeficiency disease . Concurrent recent scabies infection . Signs symptoms current infection require antibiotic treatment . Tympanic temperature Baseline &gt; 38 °C ( 100.4 °F ) pediatric patient 37.8 °C ( 100 °F ) adult patient . Use systemic topical antibiotic steroid within 72 hour prior study entry . Participation clinical study use investigational drug investigational device within 30 day prior treatment . Known allergy constituent study medication . Presence secondarilyinfected animal/human/insect bite infect burn wound . Other reason base discretion investigator make patient unsuitable enrolment . Lactating pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Impetigo</keyword>
	<keyword>LTX-109</keyword>
	<keyword>Topical</keyword>
	<keyword>Antibiotic</keyword>
	<keyword>Placebo</keyword>
	<keyword>Lytic</keyword>
	<keyword>Peptide</keyword>
	<keyword>Gram Positive</keyword>
</DOC>